• Something wrong with this record ?

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

BC. Cho, R. Obermannova, A. Bearz, M. McKeage, DW. Kim, U. Batra, G. Borra, S. Orlov, SW. Kim, SL. Geater, PE. Postmus, SA. Laurie, K. Park, CT. Yang, A. Ardizzoni, AC. Bettini, G. de Castro, F. Kiertsman, Z. Chen, YY. Lau, K. Viraswami-Appanna,...

. 2019 ; 14 (7) : 1255-1265. [pub] 20190307

Language English Country United States

Document type Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20023855

INTRODUCTION: In an earlier report of the ASCEND-8 study (open-label, phase I, three-arm study, treatment-naive patients and pre-treated patients with advanced/metastatic NSCLC), it was shown that ceritinib 450 mg with food had comparable exposure and better gastrointestinal tolerability than 750-mg fasted. METHODS: Here, we report efficacy and updated safety data from primary efficacy analysis of the ASCEND-8 study. Key secondary endpoints were overall response rate and duration of response, assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors 1.1. RESULTS: In total, 306 patients were randomized to ceritinib 450-mg fed (n = 108) or 600-mg fed (n = 87) or 750-mg fasted (n = 111), of which 304 patients were included in safety analysis and 198 treatment-naive patients (ALK receptor tyrosine kinase [ALK]-positive by immunohistochemistry) were included in the efficacy analysis (450-mg fed [n = 73], 600-mg fed [n = 51], and 750-mg fasted [n = 74]). The BIRC-assessed overall response rate was 78.1% (95% confidence interval [CI]: 66.9-86.9), 72.5% (95% CI: 58.3-84.1), and 75.7% (95% CI: 64.3-84.9), respectively; and the median duration of response (months) by BIRC was not estimable (NE) (95% CI: 11.2-NE), 20.7 (95% CI: 15.8-NE), and 15.4 (95% CI: 8.3-NE), respectively. Based on the safety analysis (n = 304), the 450-mg fed arm showed the highest median relative dose intensity (100% versus 78.5% versus 83.7%), lowest proportion of patients with dose reductions (24.1% versus 65.1% versus 60.9%), and lowest proportion of patients with gastrointestinal toxicities (75.9% versus 82.6% versus 91.8%). CONCLUSION: Ceritinib at a dose of 450 mg with food compared to 750-mg fasted showed consistent efficacy and less gastrointestinal toxicity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023855
003      
CZ-PrNML
005      
20201214131439.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jtho.2019.03.002 $2 doi
035    __
$a (PubMed)30851442
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cho, Byoung Chul $u Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: CBC1971@yuhs.ac.
245    10
$a Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study / $c BC. Cho, R. Obermannova, A. Bearz, M. McKeage, DW. Kim, U. Batra, G. Borra, S. Orlov, SW. Kim, SL. Geater, PE. Postmus, SA. Laurie, K. Park, CT. Yang, A. Ardizzoni, AC. Bettini, G. de Castro, F. Kiertsman, Z. Chen, YY. Lau, K. Viraswami-Appanna, VQ. Passos, R. Dziadziuszko,
520    9_
$a INTRODUCTION: In an earlier report of the ASCEND-8 study (open-label, phase I, three-arm study, treatment-naive patients and pre-treated patients with advanced/metastatic NSCLC), it was shown that ceritinib 450 mg with food had comparable exposure and better gastrointestinal tolerability than 750-mg fasted. METHODS: Here, we report efficacy and updated safety data from primary efficacy analysis of the ASCEND-8 study. Key secondary endpoints were overall response rate and duration of response, assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors 1.1. RESULTS: In total, 306 patients were randomized to ceritinib 450-mg fed (n = 108) or 600-mg fed (n = 87) or 750-mg fasted (n = 111), of which 304 patients were included in safety analysis and 198 treatment-naive patients (ALK receptor tyrosine kinase [ALK]-positive by immunohistochemistry) were included in the efficacy analysis (450-mg fed [n = 73], 600-mg fed [n = 51], and 750-mg fasted [n = 74]). The BIRC-assessed overall response rate was 78.1% (95% confidence interval [CI]: 66.9-86.9), 72.5% (95% CI: 58.3-84.1), and 75.7% (95% CI: 64.3-84.9), respectively; and the median duration of response (months) by BIRC was not estimable (NE) (95% CI: 11.2-NE), 20.7 (95% CI: 15.8-NE), and 15.4 (95% CI: 8.3-NE), respectively. Based on the safety analysis (n = 304), the 450-mg fed arm showed the highest median relative dose intensity (100% versus 78.5% versus 83.7%), lowest proportion of patients with dose reductions (24.1% versus 65.1% versus 60.9%), and lowest proportion of patients with gastrointestinal toxicities (75.9% versus 82.6% versus 91.8%). CONCLUSION: Ceritinib at a dose of 450 mg with food compared to 750-mg fasted showed consistent efficacy and less gastrointestinal toxicity.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a anaplastická lymfomová kináza $x genetika $7 D000077548
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a nádory kostí $x farmakoterapie $x genetika $x sekundární $7 D001859
650    _2
$a nádory mozku $x farmakoterapie $x genetika $x sekundární $7 D001932
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x genetika $x patologie $7 D002289
650    12
$a omezení příjmu potravy $7 D005215
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a potraviny $7 D005502
650    _2
$a genová přestavba $7 D015321
650    _2
$a lidé $7 D006801
650    _2
$a nádory jater $x farmakoterapie $x genetika $x sekundární $7 D008113
650    _2
$a nádory plic $x farmakoterapie $x genetika $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a maximální tolerovaná dávka $7 D020714
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a pyrimidiny $x terapeutické užití $7 D011743
650    _2
$a kritéria léčebné odpovědi $7 D066066
650    _2
$a sulfony $x terapeutické užití $7 D013450
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Obermannova, Radka $u Masaryk Memorial Cancer Institute, Brno-střed-Staré Brno, Czech Republic.
700    1_
$a Bearz, Alessandra $u Centro di Riferimento Oncologico-IRCCS, Aviano, Italy.
700    1_
$a McKeage, Mark $u University of Auckland, Auckland, New Zealand.
700    1_
$a Kim, Dong-Wang $u Seoul National University Hospital, Seoul, Republic of Korea.
700    1_
$a Batra, Ullas $u Rajiv Gandhi Cancer Institute, Rohini, New Delhi, India.
700    1_
$a Borra, Gloria $u Az. Osp. Univ.Maggiore della Carità, Italy.
700    1_
$a Orlov, Sergey $u State Pavlov Medical University, St. Petersburg, Russia.
700    1_
$a Kim, Sang-We $u Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
700    1_
$a Geater, Sarayut L $u Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand.
700    1_
$a Postmus, Pieter E $u The Clatterbridge Centre NHS Foundation Trust, Liverpool, United Kingdom.
700    1_
$a Laurie, Scott A $u Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada.
700    1_
$a Park, Keunchil $u Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
700    1_
$a Yang, Cheng-Ta $u Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
700    1_
$a Ardizzoni, Andrea $u S.Orsola-Malpighi University Hospital, Bologna, Italy.
700    1_
$a Bettini, Anna C $u A.S.S.T. Papa Giovanni XXIII, Bergamo, Italy.
700    1_
$a de Castro, Gilberto $u Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
700    1_
$a Kiertsman, Flavia $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
700    1_
$a Chen, Zhe $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
700    1_
$a Lau, Yvonne Y $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
700    1_
$a Viraswami-Appanna, Kalyanee $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
700    1_
$a Passos, Vanessa Q $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
700    1_
$a Dziadziuszko, Rafal $u Rafal Dziadziuszko, Medical University of Gdansk, Gdansk, Poland.
773    0_
$w MED00186087 $t Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer $x 1556-1380 $g Roč. 14, č. 7 (2019), s. 1255-1265
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30851442 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131436 $b ABA008
999    __
$a ok $b bmc $g 1596174 $s 1114531
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c 7 $d 1255-1265 $e 20190307 $i 1556-1380 $m Journal of thoracic oncology $n J Thorac Oncol $x MED00186087
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options